Wegovy.Overview

A weekly injection that cuts body weight by 20% in a clinical trial is the kind of stat that launches a thousand headlines. But Wegovy is not a cosmetic quick fix — it’s a long‑term medication for a chronic disease, and the numbers get messier the closer you look.

Quick Answer

Wegovy is an FDA‑approved medication for chronic weight management — a once‑weekly shot or a daily pill containing semaglutide, a drug that mimics a gut hormone called GLP‑1 to reduce appetite. It’s approved for adults with obesity (BMI 30+) or overweight (BMI 27+) plus at least one weight‑related health problem, and for adolescents aged 12 and older with obesity. It also lowers the risk of major heart events by roughly 20% in adults with cardiovascular disease who are overweight or have obesity, and treats noncirrhotic MASH (metabolic dysfunction‑associated steatohepatitis — a type of fatty liver disease with inflammation and liver damage, but without cirrhosis).

In clinical trials, people lost an average of 14% to 21% of their starting body weight. The most common side effects are nausea, diarrhea, and vomiting. The label carries a boxed warning for a rare thyroid cancer risk. And most people who stop regain a significant chunk of the weight they lost.

How Wegovy Works

Semaglutide mimics GLP‑1, a gut hormone your body releases after you eat. It binds to receptors in the brain, pancreas, and digestive tract, turning down appetite, slowing stomach emptying, and prompting more insulin when blood sugar rises. Together, those signals reduce how much you eat.

Exactly how it lowers cardiovascular events — and some of its brain effects — isn’t fully understood yet.

How You Take Wegovy: Injection vs. Pill

Wegovy is available as a once‑weekly injection (pre‑filled, single‑use pens) and a once‑daily tablet. Both start at a low dose and ramp up slowly over several weeks to a target maintenance dose — a strategy that reduces early gastrointestinal misery. Your doctor decides the pace and the final dose based on how you respond.

A higher‑strength injection (7.2 mg, called Wegovy HD) exists for people who need additional weight loss after reaching the standard maintenance dose; the prescriber decides when that step makes sense.

The tablet comes with specific absorption requirements — including an empty stomach and a short wait before eating — that your doctor will walk you through.

What the Clinical Trials Actually Show

All results come from large, randomized trials where participants also cut calories and moved more. They’re group averages — not a personal guarantee.

Some body‑composition studies, including the STEP 1 sub‑study, found that up to 40–60% of the weight lost on treatment can be lean mass — muscle, not just fat.

Wegovy vs. Ozempic

Both contain semaglutide, but confusing them causes problems with dosing, insurance, and safety.

| | Wegovy | Ozempic | |--|--------|---------| | FDA‑approved use | Chronic weight management; cardiovascular risk reduction in overweight/obesity; MASH; adolescent obesity | Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes | | Maximum weekly injection dose | 2.4 mg (or 7.2 mg HD) | 2.0 mg | | Formulations | Weekly injection + daily pill | Weekly injection only (oral semaglutide for diabetes is sold as Rybelsus) |

Someone with type 2 diabetes on Ozempic may lose weight, but Ozempic is not a weight‑loss drug. Wegovy is not approved to treat diabetes, even though the active ingredient is identical.

Safety: Side Effects and Warnings

Nausea is the most common side effect, followed by diarrhea, constipation, vomiting, and stomach pain. These symptoms usually peak during the first months of dose increases and often ease with time.

The FDA label carries a boxed warning, its strongest caution: Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The risk was seen in rodent studies; we don’t know if it applies to humans, but the warning exists because it can’t be ruled out.

Other serious risks listed in the label:

As of the January 2026 label update, the FDA removed the warning about suicidal behavior and ideation after an extensive review found insufficient evidence of a causal link.

Seek emergency care if you have severe abdominal pain that radiates to your back, persistent vomiting, a rapid or irregular heartbeat, signs of a severe allergic reaction (swelling of the face or throat, trouble breathing), or symptoms of severe dehydration (dizziness, fainting, very dark urine).

Pregnancy: Wegovy isn’t recommended. The general guidance is to stop at least two months before a planned pregnancy; breastfeeding requires a risk‑benefit conversation with your doctor.

For a deeper look at adverse reactions, see Wegovy side effects.

Cost and Insurance

The list price without insurance for the weekly injection is around ,349 for a 28‑day supply. Most people don’t pay that.

Medicare and Medicaid enrollees can’t use the savings card; coverage depends on your plan’s formulary.

The same savings card, cash‑pay subscription, and introductory pricing apply to the tablet — so the financial access programs are essentially identical whether you use the injection or the pill. Exact out‑of‑pocket costs still vary by pharmacy and your plan’s preferred drug list.

What Happens When You Stop

Wegovy is designed for continuous use. When people stop, the weight returns fast.

A year after discontinuing semaglutide, patients in one major analysis had regained about 60% of what they lost — retaining roughly 25% of the original loss longer term. There is concern that muscle lost during treatment may be replaced disproportionately by fat during regain, but direct body‑composition studies tracking regain after GLP‑1 discontinuation are sparse — we don’t yet know the exact composition of regained weight.

That’s why obesity medicine specialists treat this as an ongoing therapy for a chronic disease, not a temporary diet aid.

What the Internet Gets Wrong

“Ozempic face” isn’t a diagnosis. Loss of facial volume can happen with any large, rapid weight reduction — it’s not specific to GLP‑1 drugs.

Wegovy is just Ozempic at a higher dose. Confusing the two leads to dose errors and insurance denials.

Celebrity before‑and‑after photos don’t prove medication use — let alone guarantee it will work the same way for you.

The pill isn’t just “the injection without the needle.” It has its own dosing rules, food restrictions, and trial data (OASIS 4, not STEP).

Trial averages aren’t promises. Many people lose significantly less than the headline number; a meaningful percentage lose less than 5%.

Compounded semaglutide is not Wegovy. It’s not FDA‑approved, not made by Novo Nordisk, and the FDA has explicitly warned against it.

The MASH approval doesn’t mean Wegovy cures liver disease. It treats a specific stage of noncirrhotic MASH based on histologic improvement in patients with moderate‑to‑advanced fibrosis but without cirrhosis. It has not been studied in patients with cirrhosis.

Wegovy isn’t a short‑term cosmetic tool. It treats obesity — a recognized chronic disease — and stopping typically brings the weight back.

The Reality of Long‑Term Treatment

Wegovy can be a powerful tool when the medical criteria are met. But it demands a sustained partnership with a healthcare professional. Starting it because a TikTok convinced you — or stopping it because the nausea got old — can leave you worse off than before. The evidence is strong, the commitment is real.

Frequently Asked Questions

What’s the actual difference between Wegovy and Ozempic? Same active ingredient, different approved uses. Ozempic treats type 2 diabetes at a maximum 2.0 mg dose; Wegovy is for weight management at 2.4 mg (or 7.2 mg HD). The pill exists only as Wegovy — Ozempic has no oral form. Swapping one for the other is not a safe swap.

Is there really a Wegovy pill? Yes, approved in December 2025. It’s a once‑daily tablet taken under specific conditions your healthcare professional will explain. The dose steps up slowly to a maintenance level, just like the injection.

How much weight can someone expect to lose? Clinical trials averaged 14% to 21% of starting weight, but individual results ranged from very little loss to over 30%. Depending on the study, up to 40–60% of the lost weight can be lean mass, not just fat.

What are the most common side effects? Nausea, diarrhea, constipation, vomiting, and stomach pain — usually most intense during the first few months and often fading. Adjusting eating habits sometimes helps, but that’s not a substitute for professional guidance on managing side effects.

Does Wegovy have a savings card or coupon? Yes. People with commercial insurance can use the manufacturer’s savings card to pay as little as $0–$25 per month, capped at $4,600 per year. Cash‑pay prices start at $349/month through NovoCare, with subscription plans as low as $249/month. Medicare and Medicaid enrollees aren’t eligible for the card.

What happens after stopping Wegovy? Most people regain about 60% of lost weight within a year, though roughly 25% of the initial loss may be maintained longer term. Wegovy is intended as an ongoing treatment, not a one‑time course.

How does Wegovy compare to Zepbound? Zepbound (tirzepatide) activates both GIP and GLP‑1 receptors; Wegovy targets only GLP‑1. In a head‑to‑head trial (SURMOUNT‑5), Zepbound led to 20.2% average weight loss vs 13.7% for Wegovy 2.4 mg. No head‑to‑head data yet exist against Wegovy’s 7.2 mg HD dose. The right choice depends on medical history, side‑effect tolerance, and insurance coverage — not just a number from a separate trial.

This article is for general education only and does not replace medical advice from a licensed healthcare professional.